U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsych

Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6%

Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's par

Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate,

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and m

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regu

Biohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and

Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epile

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enro

In June 2026, we announced that enrollment in BHV7000-303 was complete. Dosing continues and topline

RBC Capital analyst Leonid Timashev downgrades Biohaven (NYSE:BHVN) from Outperform to Sector Per

BlackRock Inc. bought a new stake in shares of Biohaven Ltd. (NYSE: BHVN) during the undefined quart

Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.

Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a ke

Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global right

Biohaven Ltd. (NYSE:BHVN) scored two major wins this week. The company signed a lucrative licensing

Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair e

Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion

Biohaven has ​entered into ‌a licensing agreement ​with ​South Korean drug ⁠maker ​SK Biopharmaceuti

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $7

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $7

 Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE:BHVN) and Yale Univer

NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd.

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises t

Biohaven (NYSE:BHVN) reported quarterly losses of $(0.78) per share which missed the analyst consens

First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic eff

Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to B

The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade sec

NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd.

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combina

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga

Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets.

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.

Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discover

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underper

BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degr

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company f

Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company fo

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and m

Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discove

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers t

https://www.sec.gov/Archives/edgar/data/1935979/000162828026029834/biohavens-3asr.htm